Last reviewed · How we verify
Amelogenin
At a glance
| Generic name | Amelogenin |
|---|---|
| Also known as | third molar surgery |
| Sponsor | University of Roma La Sapienza |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- AMG 334 20160172 Pediatric Migraine PK Study. (PHASE1)
- Allograft With Enamel Matrix Derivative Versus Allograft Alone in the Treatment of Intrabony Defects . (NA)
- Treatment of Intraosseous Periodontal Defects With Amelogenins (NA)
- Entire Papilla Preservation Technique With and Without Biomaterials in the Treatment of Isolated Intrabony Defects (NA)
- Verify if Amelogenins Had Some Benefits in Improving Lower 2nd Molar Periodontal Healing After 3rd Molar Extraction (PHASE4)
- Collagen Matrix With and Without Enamel Matrix Derivative
- Enamel Matrix Proteins in the Treatment of Intrabony Defects in Patients With Aggressive and Chronic Periodontitis (PHASE4)
- Amelogenins and Systemic Inflammation After Periodontal Surgical Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |